NCT00002300

Brief Summary

To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To characterize dose response in relation to weight gain. To determine whether megestrol acetate relative to placebo improves the perception of well-being among AIDS patients with cachexia. To evaluate megestrol acetate's effect on immune function via skin test reactivity, T4/T8 ratio, and total lymphocytes.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

15 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 1999

Completed
1.8 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

October 2, 2007

Status Verified

October 1, 2007

First QC Date

November 2, 1999

Last Update Submit

October 1, 2007

Conditions

Keywords

T-LymphocytesMegestrolDose-Response Relationship, DrugAcquired Immunodeficiency SyndromeAnorexiaCachexia

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient must have:
  • Confirmed diagnosis of AIDS (CDC definition).
  • Documented weight loss or anorexia.
  • Life expectancy = or \> 20 weeks.
  • The perception that the weight loss is a detriment to their well-being.
  • Ability to provide informed consent, read and write English.
  • Prior Medication:
  • Allowed:
  • Ganciclovir.

You may not qualify if:

  • Co-existing Condition:
  • Patients with the following are excluded:
  • Dementia or evidence of mental incompetence which would preclude compliance with the protocol.
  • Diarrhea defined as 5 or more watery stools per day for at least 7 days.
  • Active uncontrolled systemic infections at the start of treatment.
  • (Patients may not be entered for at least 2 weeks after acute infection.) Clinical or radiologic evidence of ascites or pleural effusions.
  • Concurrent Medication:
  • Excluded:
  • Therapy designed to treat the underlying HIV infection or which may have a major impact on appetite and/or weight gain.
  • Patients who have been started on zidovudine (AZT) within eight weeks. (Patients may have been previously treated with AZT and failed or may currently be receiving AZT for at least 8 weeks.)
  • Patients with the following are excluded:
  • Obstruction to food intake or impaired digestive/absorptive functions.
  • Contraindications to high-dose megestrol acetate (poorly controlled hypertension or heart failure or deep vein thrombosis).
  • Inability to consent or be available for close follow-up.
  • Active systemic infections at the start of treatment.
  • +12 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (15)

Birmingham Veterans Administration Med Ctr / Univ of Alabama

Birmingham, Alabama, 35233, United States

Location

Dr NS Tchekmedyian

Long Beach, California, 90801, United States

Location

Dr Stephen J Gabin Jr

Los Angeles, California, 90067, United States

Location

Eisenhower Med Ctr

Rancho Mirage, California, 92270, United States

Location

Denver Public Health Dept

Denver, Colorado, 80204, United States

Location

George Washington Univ Med Ctr

Washington D.C., District of Columbia, 20037, United States

Location

Veterans Administration Med Ctr

Washington D.C., District of Columbia, 20422, United States

Location

Miami Veterans Administration Med Ctr

Miami, Florida, 33125, United States

Location

Northwestern Univ Med School

Chicago, Illinois, 60611, United States

Location

Albany Med College / AIDS Treatment Ctr

Albany, New York, 12203, United States

Location

Community Research Initiative on AIDS

New York, New York, 10010, United States

Location

Saint Vincent's Hosp and Med Ctr

New York, New York, 10011, United States

Location

Mem Sloan - Kettering Cancer Ctr

New York, New York, 10021, United States

Location

Univ of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Audie L Murphy Veterans Administration Hosp

San Antonio, Texas, 78284, United States

Location

Related Publications (1)

  • Strang P. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Anticancer Res. 1997 Jan-Feb;17(1B):657-62.

    PMID: 9066597BACKGROUND

MeSH Terms

Conditions

AnorexiaCachexiaHIV InfectionsAcquired Immunodeficiency Syndrome

Interventions

Megestrol Acetate

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and SymptomsWeight LossBody Weight ChangesBody WeightThinnessBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesSlow Virus Diseases

Intervention Hierarchy (Ancestors)

MegestrolPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic Compounds

Study Design

Study Type
interventional
Phase
phase 2
Masking
DOUBLE
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 2, 1999

First Posted

August 31, 2001

Last Updated

October 2, 2007

Record last verified: 2007-10

Locations